Goldman Sachs: Hansoh Pharma maintains double-digit growth guidance for 2026, targets 30 innovative drugs by 2030
Growth in existing innovative drugs and new product launches support Hansoh Pharma's near-term targets; the company plans to expand its marketed innovative drugs from 9 to 30 by 2030, with its ADC and metabolic disease pipelines as important sources.